Bio-Works Technologies

Bio-Works two largest shareholders Staffan Persson and Erik Åfors have independently informed the company of their intention to exercise all their outstanding Warrants of series TO 2 at the forthcoming exercise period. This includes all their privately held Warrants of series TO2 and Warrant TO 2 holdings in Swedia Invest AB and Calyptra AB. 

Their combined holdings amount to 13,666,044 TO 2 Warrants. The next exercise period runs from 1–14 October 2025.

Upon exercise, Bio-Works will receive SEK 13,666,044 before issue costs.

Contacts
For more information, please visit the Bio-Works homepage at, www.bio-works.com or contact: Arne Hauge, CFO, e-mail: arne.hauge@bio-works.com, phone: +46(0)8-502 705 83.

About Bio-Works
Bio-Works enables Biotech companies to achieve their goals for purification of biomolecules. We support our customers, from laboratory research to commercial production, and together we implement efficient and robust solutions for bioprocessing. Our ambition is to be a trusted and dynamic partner in an industry characterized by growth and development.

Bio-Works’ headquarters, with R&D and manufacturing, is located in Uppsala Business Park in Uppsala, Sweden. We supply products globally, through a combination of direct sales and via distributors in Europe, North America and Asia. The company is certified according to the ISO 9001:2015 quality management system. Bio-Works is listed on Spotlight Stock Market ("BIOWKS"). For more information, visit www.bio-works.com.